# Evotec SE: overview EVO · Nasdaq · CIK 1412558 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/evo.md) · [Financials](/companies/evo/financials.md) · [Filings](/companies/evo/filings.md) · [Insiders](/companies/evo/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [501](/filings/0001104659-23-059900.md) | [618](/filings/0001104659-24-089121.md) | [751](/filings/0001104659-25-035638.md) | [781](/filings/0001104659-25-035638.md) | [797](/filings/0001104659-25-035638.md) | | Gross margin | % | [25.1%](/filings/0001104659-23-059900.md) | [24.5%](/filings/0001104659-24-089121.md) | [23.2%](/filings/0001104659-25-035638.md) | [22.4%](/filings/0001104659-25-035638.md) | [14.4%](/filings/0001104659-25-035638.md) | | Operating margin | % | [9.7%](/filings/0001104659-23-059900.md) | [6.6%](/filings/0001104659-24-089121.md) | [2.8%](/filings/0001104659-25-035638.md) | [(6.1%)](/filings/0001104659-25-035638.md) | [(17.9%)](/filings/0001104659-25-035638.md) | | Net margin | % | [1.3%](/filings/0001104659-23-059900.md) | [34.9%](/filings/0001104659-23-059900.md) | [(23.4%)](/filings/0001104659-23-059900.md) | [(10.7%)](/filings/0001104659-25-035638.md) | [(24.6%)](/filings/0001104659-25-035638.md) | | Diluted EPS | $ per share | [0.04](/filings/0001104659-23-059900.md) | [1.30](/filings/0001104659-24-089121.md) | [(0.99)](/filings/0001104659-25-035638.md) | [(0.47)](/filings/0001104659-25-035638.md) | [(1.11)](/filings/0001104659-25-035638.md) | | Free cash flow | $m | [(54.4)](/filings/0001104659-23-059900.md) | [7.7](/filings/0001104659-24-089121.md) | [24.5](/filings/0001104659-25-035638.md) | [(177)](/filings/0001104659-25-035638.md) | [(99.2)](/filings/0001104659-25-035638.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue; Net income: ifrs-full:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/evo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [DCF Advisers, LLC](/funds/1802493.md) | 2026-06-30 | $3.0m | 1,079,024 | | Added +13,750 | | [WCM INVESTMENT MANAGEMENT, LLC](/funds/1061186.md) | 2026-06-30 | $1.9m | 671,884 | | Added +44,624 | | [ABC ARBITRAGE SA](/funds/2049221.md) | 2026-06-30 | $1.0m | 371,936 | | Reduced −137,114 | | [Optiver Holding B.V.](/funds/1859606.md) | 2026-06-30 | $902.0k | 322,153 | | Added +38,577 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $576.1k | 205,763 | | Reduced −53,981 | | [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $464.9k | 166,045 | | Added +43,699 | | [ENVESTNET ASSET MANAGEMENT INC](/funds/1407543.md) | 2026-06-30 | $390.9k | 139,596 | | Added +20,187 | | [OLD MISSION CAPITAL LLC](/funds/1455915.md) | 2026-06-30 | $106.5k | 38,032 | | Added +18,690 | | [Pathstone Holdings, LLC](/funds/2011612.md) | 2026-06-30 | $100.2k | 35,779 | | Added +1,652 | | [Fore Capital, LLC](/funds/1714672.md) | 2026-06-30 | $87.8k | 31,355 | | Unchanged | ## Recent filings [All 149 filings](/companies/evo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-15 | 12:43 ET | [6-K](/filings/0001104659-26-116003.md) | Report of a foreign private issuer, period 2026-10-15 | 0001104659-26-116003 | | 2026-10-14 | 21:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-115869.md) | Ownership report, active investor, amended | 0001104659-26-115869 | | 2026-10-14 | 10:02 ET | [6-K](/filings/0001104659-26-115678.md) | Report of a foreign private issuer, period 2026-10-14 | 0001104659-26-115678 | | 2026-09-29 | 10:01 ET | [6-K](/filings/0001104659-26-111508.md) | Report of a foreign private issuer, period 2026-09-29 | 0001104659-26-111508 | | 2026-09-09 | 10:05 ET | [6-K](/filings/0001104659-26-106064.md) | Report of a foreign private issuer, period 2026-09-09 | 0001104659-26-106064 | | 2026-08-13 | 10:05 ET | [6-K](/filings/0001104659-26-095267.md) | Report of a foreign private issuer, period 2026-08-13 | 0001104659-26-095267 | | 2026-07-14 | 21:54 ET | [6-K](/filings/0001104659-26-083179.md) | Report of a foreign private issuer, period 2026-07-13 | 0001104659-26-083179 | | 2026-06-30 | 17:01 ET | [6-K](/filings/0001104659-26-079222.md) | Report of a foreign private issuer, period 2026-06-30 | 0001104659-26-079222 | | 2026-06-17 | 10:02 ET | [6-K](/filings/0001104659-26-074806.md) | Report of a foreign private issuer, period 2026-06-17 | 0001104659-26-074806 | | 2026-05-06 | 13:39 ET | [6-K](/filings/0001104659-26-055957.md) | Report of a foreign private issuer, period 2026-05-06 | 0001104659-26-055957 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-040767.md), filed Apr 8, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1412558 - Tickers: EVO, EVOTF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: 2M - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.